The value of Medical Affairs is increasingly measured not only by activity volume, but by the quality of scientific engagement, the relevance of insights generated, and the function’s contribution to evidence-based healthcare decision-making.

The MSL as a Scientific Partner

MSLs are field-based scientific experts who engage external stakeholders in high-level, non-promotional scientific exchange. Their role requires a balance of scientific credibility, strategic thinking, emotional intelligence, and compliance discipline.

An effective MSL does more than deliver data; they understand the clinical context in which that data is used. For example, when discussing a new oncology therapy, an MSL should be able to explain the mechanism of action, efficacy outcomes, safety profile, patient selection considerations, biomarker relevance, and how the data may fit within existing treatment paradigms. At the same time, the MSL must ensure that all discussions remain scientifically balanced, evidence-based, and aligned with applicable laws, regulations, and company policies.

MSLs are often most effective when they approach engagements as peer-to-peer scientific conversations rather than presentations. This includes asking thoughtful questions, listening carefully to the stakeholder’s perspective, and identifying unmet needs or evidence gaps that may be relevant to the broader medical strategy.

Best Practices for KOL Engagement

KOL engagement is one of the most important responsibilities within Medical Affairs. High-quality KOL relationships are built on trust, scientific credibility, and mutual respect. These relationships should never be transactional or promotional; they should be grounded in legitimate scientific exchange and a shared interest in improving patient outcomes.

Before engaging a KOL, MSLs should conduct thorough preparation. This includes reviewing the KOL’s publication history, clinical trial involvement, congress presentations, research interests, treatment philosophy, and institutional priorities. Understanding the stakeholder’s scientific focus enables a more meaningful and relevant discussion.

During the engagement, best practices include:

• Opening with a clear scientific purpose for the discussion.
• Tailoring the conversation to the stakeholder’s expertise and interests.
• Presenting data accurately, fairly, and in context.
• Distinguishing clearly between approved information and investigational or off-label data.
• Asking open-ended questions to understand clinical perspectives and unmet needs.
• Documenting actionable insights in accordance with company policy.

For example, if a KOL expresses concern about the generalizability of pivotal trial data to elderly patients with multiple comorbidities, that insight may reveal an important evidence gap. Medical Affairs teams may use such insights to inform real-world evidence planning, future data generation, advisory board topics, or medical education priorities.

Scientific Communication and Data Interpretation

Scientific communication is a core competency for Medical Affairs professionals. MSLs must be able to communicate complex information clearly while maintaining scientific rigor. This includes explaining clinical endpoints, trial design, statistical concepts, safety considerations, and limitations of available evidence.

Balanced communication is critical. When presenting a clinical study, Medical Affairs professionals should discuss not only the primary efficacy findings but also the study population, comparator, duration of follow-up, adverse events, subgroup analyses, and limitations. Selective presentation of favorable data can undermine credibility and create compliance risk.

A strong scientific discussion often includes:

• The clinical question the study was designed to answer.
• The relevance of the patient population and inclusion criteria.
• The appropriateness of endpoints and comparators.
• The magnitude and clinical meaningfulness of the results.
• Safety and tolerability findings.
• Limitations and areas where further research is needed.

For instance, a statistically significant improvement in progression-free survival may be clinically meaningful in one disease setting but less compelling in another if the benefit is modest, toxicity is substantial, or overall survival data remain immature. MSLs must be prepared to help stakeholders interpret data within the broader clinical landscape.

Compliance Considerations in Medical Affairs

Compliance is fundamental to Medical Affairs. MSLs and Medical Affairs professionals must operate within applicable regulatory frameworks and internal policies, including FDA and EMA expectations, local codes of practice, anti-kickback regulations, privacy laws, and company-specific standard operating procedures.

A key distinction is the difference between scientific exchange and promotion. Scientific exchange is objective, balanced, and evidence-based. Promotional communication is designed to encourage use of a product and is typically restricted to approved labeling and commercial channels. Medical Affairs professionals must be careful not to present information in a way that could be interpreted as promoting an unapproved product or unapproved use.

When responding to unsolicited questions about off-label information, MSLs should follow company-approved processes. Responses should be scientifically accurate, balanced, narrowly tailored to the question asked, and appropriately documented. Proactive discussion of off-label data should generally be avoided unless clearly permitted under applicable policy and regulatory guidance.

Compliance considerations also apply to advisory boards, speaker interactions, investigator-sponsored research, congress activities, and publications. Legitimate scientific need, fair market value, appropriate documentation, and transparency are essential. Medical Affairs teams should work closely with legal, compliance, regulatory, and pharmacovigilance colleagues to ensure activities are properly governed.

Publications and Good Publication Practice

Publications are a critical mechanism for disseminating scientific evidence to the medical community. Medical Affairs teams often contribute to publication strategy, data interpretation, author engagement, and congress planning. These activities should align with Good Publication Practice principles, which emphasize transparency, accuracy, author accountability, and ethical data reporting.

A robust publication plan should be evidence-driven and aligned with legitimate scientific objectives. It should prioritize timely dissemination of clinical trial results, real-world evidence, safety analyses, and other data that address meaningful scientific or clinical questions.

Important publication principles include:

• Ensuring authors meet recognized authorship criteria.
• Avoiding ghostwriting and inappropriate authorship attribution.
• Disclosing conflicts of interest and funding sources.
• Reporting data accurately, including negative or inconclusive findings.
• Maintaining clear documentation of publication decisions and processes.

For MSLs, publications are also essential tools for field scientific exchange. However, they must be used appropriately. MSLs should understand the strengths and limitations of each publication they discuss and avoid overstating conclusions beyond what the data support.

Field Medical Insights and Strategic Value

One of the most important contributions of MSL teams is the generation of high-quality field medical insights. These insights are not simple call notes or summaries of stakeholder opinions. Rather, they are meaningful observations that identify scientific trends, clinical challenges, evidence gaps, or changes in the external environment.

Examples of valuable field medical insights include:

• Clinicians are uncertain how to sequence therapies after progression on a specific regimen.
• Community practices face barriers implementing biomarker testing.
• Investigators see a need for real-world data in underrepresented patient populations.
• Payers are requesting comparative effectiveness data to inform access decisions.
• KOLs are concerned that trial eligibility criteria do not reflect routine clinical practice.

High-quality insights should be specific, evidence-informed, and actionable. Medical Affairs teams should have a structured process for collecting, analyzing, and sharing insights with appropriate internal stakeholders. When done effectively, field insights can inform medical strategy, evidence generation, publication planning, educational initiatives, and lifecycle management.

Cross-Functional Collaboration

Medical Affairs operates at the intersection of clinical development, regulatory affairs, pharmacovigilance, health economics and outcomes research, market access, commercial teams, and external stakeholders. Effective collaboration is essential, but roles and boundaries must be clearly defined.

For example, Medical Affairs may collaborate with commercial colleagues to understand healthcare provider educational needs or congress priorities. However, Medical Affairs should maintain independence in scientific content development and ensure that all activities remain non-promotional where required. Similarly, Medical Affairs may work with clinical development to communicate external insights that could inform future study design, but decisions must remain grounded in scientific and ethical considerations.

Strong cross-functional collaboration requires clear governance, documented processes, and mutual respect for each function’s responsibilities. Medical Affairs professionals are often most valuable when they bring an external scientific perspective into internal planning discussions.

Real-World Example: Translating Insights Into Evidence Generation

Consider a scenario in which MSLs supporting a new immunology therapy repeatedly hear from rheumatologists that pivotal trial data do not fully address patients with multiple prior biologic failures. The MSL team documents these insights consistently across regions and identifies this as a recurring evidence gap.

Medical Affairs reviews the insights and collaborates with real-world evidence and clinical development colleagues to evaluate whether additional data generation is warranted. This may lead to a retrospective chart review, registry analysis, or prospective observational study designed to better understand outcomes in this patient subgroup.

The resulting data may eventually support a congress presentation or peer-reviewed publication, helping clinicians make more informed treatment decisions. This example illustrates how compliant scientific engagement can generate actionable insights that ultimately improve evidence dissemination and patient care.

Building Capabilities in Medical Affairs

As the Medical Affairs function evolves, professionals must continue to build capabilities beyond scientific expertise. Modern Medical Affairs teams increasingly rely on data analytics, digital engagement, omnichannel communication, real-world evidence, and advanced stakeholder mapping.

Core capabilities for Medical Affairs professionals and MSLs include:

• Deep therapeutic area and product knowledge.
• Critical appraisal of clinical literature.
• Clear and balanced scientific communication.
• Thorough understanding of regulatory and compliance requirements.
• Strategic KOL engagement planning.
• Insight generation and synthesis.
• Effective cross-functional collaboration.
• Strategic business acumen maintained without promotional bias.
• Digital fluency and virtual engagement skills.

Formal professional development, mentorship, therapeutic training, and credentialing programs such as the Board Certified Medical Affairs Specialist (BCMAS) program may help Medical Affairs professionals strengthen their knowledge base and demonstrate commitment to the field.

Conclusion

Medical Affairs professionals and MSLs are essential to the responsible exchange of scientific information across the healthcare ecosystem. Their work supports evidence-based decision-making, identifies unmet medical needs, informs data generation, and strengthens relationships with the scientific community.

To be effective, Medical Affairs teams must combine scientific excellence with strategic thinking, ethical judgment, and strong communication skills. Whether engaging KOLs, interpreting clinical data, supporting publications, or generating field insights, the ultimate objective remains the same: advancing medical understanding and improving patient outcomes through credible, compliant, and meaningful scientific exchange.